# KEYNOTE-059 (NCT02335411)

> A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab; pembrolizumab plus cisplatin plus 5-fluorouracil; pembrolizumab plus cisplatin plus capecitabine
- Indication: recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02335411
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
- Interventions: pembrolizumab; cisplatin; 5-FU; capecitabine
- Enrollment: 318
- Primary outcome: Number of Participants Experiencing Adverse Events (AEs)
- Primary outcome: Number of Participants Discontinuing Study Drug Due to AEs
- Primary outcome: Objective Response Rate (ORR) For All Participants in Cohorts 1 and 3
- Primary outcome: Objective Response Rate For PD-L1 Positive Participants in Cohorts 1 and 3

## Indexed commentary on KEYNOTE-059 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11
- YouTube: 1
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keynote-059-nct02335411

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02335411", "email": "<work email>"}; the inbox owner confirms by the emailed link.